Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis -March 11, 2024 at 02:01 am EDT
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and...